How Early Can Imaging Assess Response in End-Stage Prostate Cancer?
177Lu-PSMA SPECT at cycle three (week 12) of six cycles of PSMA-targeted treatment predicted progression-free survival for men with end-stage metastatic castration-resistant prostate cancer.
Source: medscape.com